Advancing patient care


Strategic collaborations that can help build market share and enhance revenue streams

Assertio is currently involved in two forms of strategic partnerships:

  • Commercialization partnerships — Out-licensing internally developed drugs to commercialization partners worldwide (often while retaining rights in selected countries/market segments)
  • Development and commercialization partnerships — Collaborating with companies looking to use Acuform® technology to enhance their own pharmaceutical products

Current development and commercialization partnerships

A commercialization agreement was signed in December 2017 for the U.S. commercialization rights to NUCYNTA® ER and NUCYNTA® for the management of pain.
A licensing agreement was established in July 2011 granting Ironwood worldwide rights to Acuform technology for the development of IW3718 for the potential treatment of refractory gastroesophageal reflux disease (GERD).
A license agreement was established in March 2011 granting Boehringer Ingelheim worldwide rights to Acuform technology for the development and commercialization of certain fixed-dose combination products including extended-release metformin and proprietary Boehringer Ingelheim compounds in development for type 2 diabetes.
  A license and development agreement was established in November 2008 granting Mallinckrodt an option to license Acuform technology to develop and commercialize up to four pharmaceutical products.
  A license agreement was established in August 2010 granting Janssen Pharmaceutica worldwide rights to Acuform technology for the development of a fixed-dose combination formulation of canagliflozin (a SGLT2 inhibitor) and extended-release metformin.


To learn more, visit the News Releases section of this website.